United States Biotechnology & Medical Research

TriSalus Life Sciences Inc (TLSI)

Track

Track

TriSalus Life Sciences Inc. experienced notable insider activity on May 15, 2026, characterized by significant share acquisitions from multiple individuals. Prior to this, various executives executed sales throughout March 2026. As these transactions occurred over three months ago, no assessment regarding current market valuation or recent performance trends is provided.
Ticker: TLSI Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for TriSalus Life Sciences Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.7
Marshak Richard Chief Commercial Officer Officer
Transaction date
Sale
Price
175.48
Quantity 71,466 +7.6%
Value US$3,996,780
3.4
Stansky Michael P Non-Executive Director
Transaction date
Purchase
Price
15.41
Quantity 39,933 -15.5%
Value US$1,683,273
3.4
Stansky Michael P Non-Executive Director
Transaction date
Purchase
Price
48.54
Quantity 56,009 +6.1%
Value US$4,836,887
4.1
Patience David Chief Financial Officer Officer
Transaction date
Purchase
Price
2.43
Quantity 7,100 +2.6%
Value US$17,253
3.1
Wahlstrom Mats Non-Executive Director
Transaction date
Purchase
Price
2.53
Quantity 60,000 +68.5%
Value US$151,800
3.4
Gordon Gary B. Non-Executive Director
Transaction date
Purchase
Price
2.46
Quantity 10,000 +16.0%
Value US$24,600
2.2
Szela Mary T CEO and President Executive Director
Transaction date
Purchase
Price
2.59
Quantity 39,682 +3.9%
Value US$102,776
2.2
Szela Mary T CEO and President Executive Director
Transaction date
Sale
Price
3.85
Quantity 15,944 -2.1%
Value US$61,384
2.7
Marshak Richard Chief Commercial Officer Officer
Transaction date
Sale
Price
4.12
Quantity 419 -0.4%
Value US$1,726
2.6
Devlin Jodi Chief of Clinical Operations Officer
Transaction date
Sale
Price
4.12
Quantity 273 -0.3%
Value US$1,125
2.8
Cox Bryan F. Chief of Research Officer
Transaction date
Sale
Price
4.12
Quantity 579 -0.4%
Value US$2,385
2.6
Stevens Jennifer Chief Regulatory Officer Officer
Transaction date
Sale
Price
4.12
Quantity 774 -0.6%
Value US$3,189
2.7
Marshak Richard Chief Commercial Officer Officer
Transaction date
Sale
Price
4.09
Quantity 1,589 -1.4%
Value US$6,499
2.6
Devlin Jodi Chief of Clinical Operations Officer
Transaction date
Sale
Price
4.09
Quantity 1,772 -1.8%
Value US$7,247
2.8
Cox Bryan F. Chief of Research Officer
Transaction date
Sale
Price
4.09
Quantity 1,467 -0.9%
Value US$6,000
2.6
Stevens Jennifer Chief Regulatory Officer Officer
Transaction date
Sale
Price
4.09
Quantity 1,552 -1.2%
Value US$6,348
2.7
Marshak Richard Chief Commercial Officer Officer
Transaction date
Sale
Price
4.13
Quantity 1,449 -1.3%
Value US$5,984
2.6
Devlin Jodi Chief of Clinical Operations Officer
Transaction date
Sale
Price
4.13
Quantity 1,162 -1.2%
Value US$4,799
2.8
Cox Bryan F. Chief of Research Officer
Transaction date
Sale
Price
4.13
Quantity 1,138 -0.7%
Value US$4,700
2.2
Szela Mary T CEO and President Executive Director
Transaction date
Sale
Price
4.13
Quantity 4,358 -0.6%
Value US$17,999
2.6
Stevens Jennifer Chief Regulatory Officer Officer
Transaction date
Sale
Price
4.13
Quantity 1,204 -0.9%
Value US$4,973
Valle William Non-Executive Director
Transaction date
Purchase
Price
4.10
Quantity 30,487 +inf%
Value US$124,997
3.4
Stansky Michael P Non-Executive Director
Transaction date
Purchase
Price
4.10
Quantity 117,198 +142.1%
Value US$480,512
3.4
Stansky Michael P Non-Executive Director
Transaction date
Purchase
Price
4.10
Quantity 243,900 +44.9%
Value US$999,990
2.2
Szela Mary T CEO and President Executive Director
Transaction date
Purchase
Price
4.10
Quantity 30,487 +4.1%
Value US$124,997
4.1
Patience David Chief Financial Officer Officer
Transaction date
Purchase
Price
4.10
Quantity 3,657 +1.4%
Value US$14,994
3.4
Gordon Gary B. Non-Executive Director
Transaction date
Purchase
Price
4.10
Quantity 9,756 +inf%
Value US$40,000
2.7
Marshak Richard Chief Commercial Officer Officer
Transaction date
Sale
Price
5.18
Quantity 6,597 -8.7%
Value US$34,172
2.6
Devlin Jodi Chief of Clinical Operations Officer
Transaction date
Sale
Price
5.18
Quantity 4,764 -8.3%
Value US$24,678
2.8
Cox Bryan F. Chief of Research Officer
Transaction date
Sale
Price
5.18
Quantity 4,764 -3.8%
Value US$24,678
2.6
Stevens Jennifer Chief Regulatory Officer Officer
Transaction date
Sale
Price
5.18
Quantity 8,704 -10.1%
Value US$45,087
2.6
Young James Emmett Chief Financial Officer Officer
Transaction date
Purchase
Price
5.65
Quantity 6,000 +25.0%
Value US$33,900
2.2
Szela Mary T CEO AND PRESIDENT Executive Director
Transaction date
Purchase
Price
5.28
Quantity 5,010 +1.1%
Value US$26,453
2.2
Szela Mary T CEO AND PRESIDENT Executive Director
Transaction date
Purchase
Price
5.03
Quantity 5,030 +1.2%
Value US$25,301
3.2
Murphy Sean Chief Manuf, Strategy&Bus Dev. Executive Director
Transaction date
Purchase
Price
5.17
Quantity 15,000 +8.2%
Value US$77,550
2.2
Szela Mary T CEO AND PRESIDENT Executive Director
Transaction date
Purchase
Price
5.12
Quantity 4,716 +1.1%
Value US$24,146
3.2
Murphy Sean Chief Manuf, Strategy&Bus Dev. Executive Director
Transaction date
Purchase
Price
5.31
Quantity 15,000 +8.9%
Value US$79,650
2.2
Szela Mary T CEO AND PRESIDENT Executive Director
Transaction date
Purchase
Price
5.42
Quantity 4,826 +1.1%
Value US$26,157
2.6
Young James Emmett Chief Financial Officer Officer
Transaction date
Purchase
Price
5.40
Quantity 24,000 +inf%
Value US$129,600
3.3
Frankenius Equity AB Large shareholder
Transaction date
Purchase
Price
3.97
Quantity 62,972 +1.0%
Value US$249,999
0.5
Desai Arjun JJ Non-Executive Director
Transaction date
Sale
Price
3.69
Quantity 30,000 -10.8%
Value US$110,700
0.5
Arjun Desai Board of Directors Non-Executive Director
Transaction date
Proposed sale
Price
4.50
Quantity 30,000
Value US$135,000
3.1
Wahlstrom Mats Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.55
Quantity 5,000 +46.6%
Value US$22,750
3.1
Wahlstrom Mats Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.44
Quantity 8,687 +425.8%
Value US$38,570
3.1
Wahlstrom Mats Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.16
Quantity 2,040 +inf%
Value US$8,486
2.8
Cox Bryan F. CHIEF SCIENTIFIC & MANUFACT. Officer
Transaction date
Sale
Price
4.44
Quantity 314 -0.4%
Value US$1,394
2.2
Szela Mary T CEO AND PRESIDENT Executive Director
Transaction date
Purchase
Price
5.00
Quantity 6,000 +1.6%
Value US$30,000
2.2
Szela Mary T CEO AND PRESIDENT Executive Director
Transaction date
Purchase
Price
4.83
Quantity 1,295 +0.3%
Value US$6,255
2.2
Szela Mary T CEO AND PRESIDENT Executive Director
Transaction date
Purchase
Price
5.20
Quantity 7,520 +2.0%
Value US$39,104
2.2
Szela Mary T CEO AND PRESIDENT Executive Director
Transaction date
Purchase
Price
4.97
Quantity 5,000 +1.4%
Value US$24,850
3.1
Martin George Kelly Non-Executive Director
Transaction date
Sale
Price
5.50
Quantity 9 -0.0%
Value US$50
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-19 2026-05-15 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
71,466 +7.6%
175.48
US$3,996,780 		71,466 +7.6% 175.48 US$3,996,780
2026-05-18 2026-05-15 B Purchase
3.4
Stansky Michael P
Non-Executive Director
39,933 -15.5%
15.41
US$1,683,273 		39,933 -15.5% 15.41 US$1,683,273
2026-05-18 2026-05-15 B Purchase
3.4
Stansky Michael P
Non-Executive Director
56,009 +6.1%
48.54
US$4,836,887 		56,009 +6.1% 48.54 US$4,836,887
2026-05-18 2026-05-15 B Purchase
4.1
Patience David

Chief Financial Officer

Officer
7,100 +2.6%
2.43
US$17,253 		7,100 +2.6% 2.43 US$17,253
2026-05-18 2026-05-15 B Purchase
3.1
Wahlstrom Mats
Non-Executive Director
60,000 +68.5%
2.53
US$151,800 		60,000 +68.5% 2.53 US$151,800
2026-05-18 2026-05-15 B Purchase
3.4
Gordon Gary B.
Non-Executive Director
10,000 +16.0%
2.46
US$24,600 		10,000 +16.0% 2.46 US$24,600
2026-05-18 2026-05-15 B Purchase
2.2
Szela Mary T

CEO and President

Executive Director
39,682 +3.9%
2.59
US$102,776 		39,682 +3.9% 2.59 US$102,776
2026-03-20 2026-03-17 S Sale
2.2
Szela Mary T

CEO and President

Executive Director
15,944 -2.1%
3.85
US$61,384 		15,944 -2.1% 3.85 US$61,384
2026-03-20 2026-03-16 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
419 -0.4%
4.12
US$1,726 		419 -0.4% 4.12 US$1,726
2026-03-20 2026-03-16 S Sale
2.6
Devlin Jodi

Chief of Clinical Operations

Officer
273 -0.3%
4.12
US$1,125 		273 -0.3% 4.12 US$1,125
2026-03-20 2026-03-16 S Sale
2.8
Cox Bryan F.

Chief of Research

Officer
579 -0.4%
4.12
US$2,385 		579 -0.4% 4.12 US$2,385
2026-03-20 2026-03-16 S Sale
2.6
Stevens Jennifer

Chief Regulatory Officer

Officer
774 -0.6%
4.12
US$3,189 		774 -0.6% 4.12 US$3,189
2026-03-20 2026-03-12 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
1,589 -1.4%
4.09
US$6,499 		1,589 -1.4% 4.09 US$6,499
2026-03-20 2026-03-12 S Sale
2.6
Devlin Jodi

Chief of Clinical Operations

Officer
1,772 -1.8%
4.09
US$7,247 		1,772 -1.8% 4.09 US$7,247
2026-03-20 2026-03-12 S Sale
2.8
Cox Bryan F.

Chief of Research

Officer
1,467 -0.9%
4.09
US$6,000 		1,467 -0.9% 4.09 US$6,000
2026-03-20 2026-03-12 S Sale
2.6
Stevens Jennifer

Chief Regulatory Officer

Officer
1,552 -1.2%
4.09
US$6,348 		1,552 -1.2% 4.09 US$6,348
2026-03-20 2026-03-11 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
1,449 -1.3%
4.13
US$5,984 		1,449 -1.3% 4.13 US$5,984
2026-03-20 2026-03-11 S Sale
2.6
Devlin Jodi

Chief of Clinical Operations

Officer
1,162 -1.2%
4.13
US$4,799 		1,162 -1.2% 4.13 US$4,799
2026-03-20 2026-03-11 S Sale
2.8
Cox Bryan F.

Chief of Research

Officer
1,138 -0.7%
4.13
US$4,700 		1,138 -0.7% 4.13 US$4,700
2026-03-20 2026-03-11 S Sale
2.2
Szela Mary T

CEO and President

Executive Director
4,358 -0.6%
4.13
US$17,999 		4,358 -0.6% 4.13 US$17,999
2026-03-20 2026-03-11 S Sale
2.6
Stevens Jennifer

Chief Regulatory Officer

Officer
1,204 -0.9%
4.13
US$4,973 		1,204 -0.9% 4.13 US$4,973
2026-02-23 2026-02-23 B Purchase
Valle William
Non-Executive Director
30,487 +inf%
4.10
US$124,997 		30,487 +inf% 4.10 US$124,997
2026-02-23 2026-02-23 B Purchase
3.4
Stansky Michael P
Non-Executive Director
117,198 +142.1%
4.10
US$480,512 		117,198 +142.1% 4.10 US$480,512
2026-02-23 2026-02-23 B Purchase
3.4
Stansky Michael P
Non-Executive Director
243,900 +44.9%
4.10
US$999,990 		243,900 +44.9% 4.10 US$999,990
2026-02-23 2026-02-23 B Purchase
2.2
Szela Mary T

CEO and President

Executive Director
30,487 +4.1%
4.10
US$124,997 		30,487 +4.1% 4.10 US$124,997
2026-02-23 2026-02-23 B Purchase
4.1
Patience David

Chief Financial Officer

Officer
3,657 +1.4%
4.10
US$14,994 		3,657 +1.4% 4.10 US$14,994
2026-02-23 2026-02-23 B Purchase
3.4
Gordon Gary B.
Non-Executive Director
9,756 +inf%
4.10
US$40,000 		9,756 +inf% 4.10 US$40,000
2025-05-21 2025-05-19 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
6,597 -8.7%
5.18
US$34,172 		6,597 -8.7% 5.18 US$34,172
2025-05-21 2025-05-19 S Sale
2.6
Devlin Jodi

Chief of Clinical Operations

Officer
4,764 -8.3%
5.18
US$24,678 		4,764 -8.3% 5.18 US$24,678
2025-05-21 2025-05-19 S Sale
2.8
Cox Bryan F.

Chief of Research

Officer
4,764 -3.8%
5.18
US$24,678 		4,764 -3.8% 5.18 US$24,678
2025-05-21 2025-05-19 S Sale
2.6
Stevens Jennifer

Chief Regulatory Officer

Officer
8,704 -10.1%
5.18
US$45,087 		8,704 -10.1% 5.18 US$45,087
2025-02-06 2025-02-05 B Purchase
2.6
Young James Emmett

Chief Financial Officer

Officer
6,000 +25.0%
5.65
US$33,900 		6,000 +25.0% 5.65 US$33,900
2025-01-31 2025-01-30 B Purchase
2.2
Szela Mary T

CEO AND PRESIDENT

Executive Director
5,010 +1.1%
5.28
US$26,453 		5,010 +1.1% 5.28 US$26,453
2025-01-31 2025-01-29 B Purchase
2.2
Szela Mary T

CEO AND PRESIDENT

Executive Director
5,030 +1.2%
5.03
US$25,301 		5,030 +1.2% 5.03 US$25,301
2025-01-29 2025-01-28 B Purchase
3.2
Murphy Sean

Chief Manuf, Strategy&Bus Dev.

Executive Director
15,000 +8.2%
5.17
US$77,550 		15,000 +8.2% 5.17 US$77,550
2025-01-29 2025-01-28 B Purchase
2.2
Szela Mary T

CEO AND PRESIDENT

Executive Director
4,716 +1.1%
5.12
US$24,146 		4,716 +1.1% 5.12 US$24,146
2025-01-29 2025-01-27 B Purchase
3.2
Murphy Sean

Chief Manuf, Strategy&Bus Dev.

Executive Director
15,000 +8.9%
5.31
US$79,650 		15,000 +8.9% 5.31 US$79,650
2025-01-29 2025-01-27 B Purchase
2.2
Szela Mary T

CEO AND PRESIDENT

Executive Director
4,826 +1.1%
5.42
US$26,157 		4,826 +1.1% 5.42 US$26,157
2025-01-29 2025-01-27 B Purchase
2.6
Young James Emmett

Chief Financial Officer

Officer
24,000 +inf%
5.40
US$129,600 		24,000 +inf% 5.40 US$129,600
2024-12-19 2024-12-17 B Purchase
3.3
Frankenius Equity AB
Large shareholder
62,972 +1.0%
3.97
US$249,999 		62,972 +1.0% 3.97 US$249,999
2024-12-12 2024-12-10 S Sale
0.5
Desai Arjun JJ
Non-Executive Director
30,000 -10.8%
3.69
US$110,700 		30,000 -10.8% 3.69 US$110,700
2024-12-10 2024-12-10 PrS Proposed sale
0.5
Arjun Desai

Board of Directors

Non-Executive Director
30,000
4.50
US$135,000 		30,000 4.50 US$135,000
2024-11-25 2024-11-22 B Purchase
3.1
Wahlstrom Mats
Non-Executive Director Large shareholder
5,000 +46.6%
4.55
US$22,750 		5,000 +46.6% 4.55 US$22,750
2024-11-22 2024-11-21 B Purchase
3.1
Wahlstrom Mats
Non-Executive Director Large shareholder
8,687 +425.8%
4.44
US$38,570 		8,687 +425.8% 4.44 US$38,570
2024-11-22 2024-11-20 B Purchase
3.1
Wahlstrom Mats
Non-Executive Director Large shareholder
2,040 +inf%
4.16
US$8,486 		2,040 +inf% 4.16 US$8,486
2024-12-19 2024-10-05 S Sale
2.8
Cox Bryan F.

CHIEF SCIENTIFIC & MANUFACT.

Officer
314 -0.4%
4.44
US$1,394 		314 -0.4% 4.44 US$1,394
2024-09-13 2024-09-13 B Purchase
2.2
Szela Mary T

CEO AND PRESIDENT

Executive Director
6,000 +1.6%
5.00
US$30,000 		6,000 +1.6% 5.00 US$30,000
2024-09-13 2024-09-13 B Purchase
2.2
Szela Mary T

CEO AND PRESIDENT

Executive Director
1,295 +0.3%
4.83
US$6,255 		1,295 +0.3% 4.83 US$6,255
2024-09-13 2024-09-12 B Purchase
2.2
Szela Mary T

CEO AND PRESIDENT

Executive Director
7,520 +2.0%
5.20
US$39,104 		7,520 +2.0% 5.20 US$39,104
2024-09-12 2024-09-10 B Purchase
2.2
Szela Mary T

CEO AND PRESIDENT

Executive Director
5,000 +1.4%
4.97
US$24,850 		5,000 +1.4% 4.97 US$24,850
2024-09-10 2024-08-28 S Sale
3.1
Martin George Kelly
Non-Executive Director
9 -0.0%
5.50
US$50 		9 -0.0% 5.50 US$50
Explore more

More insider trading research around TriSalus Life Sciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America